000
| 02078nam 2200349za 4500 |
---|
001 | 9.842534 |
---|
003 | CaOODSP |
---|
005 | 20221107152337 |
---|
007 | cr ||||||||||| |
---|
008 | 170828s2017 onc ob f000 0 eng d |
---|
022 | |z1925-0932 |
---|
040 | |aCaOODSP|beng |
---|
043 | |an-cn--- |
---|
086 | 1 |aH113-25/2017-13E-PDF|zH113-25/2017-13E |
---|
245 | 00|aAzamethiphos |h[electronic resource]. |
---|
260 | |aOttawa : |bHealth Canada, Pest Management Regulatory Agency, |c2017. |
---|
300 | |a26 p. |
---|
490 | 1 |aRegistration decision, |x1925-0940 ; |vRD2017-13 |
---|
500 | |aIssued also in French under title: Azaméthiphos. |
---|
500 | |aCover title. |
---|
500 | |a"15 August 2017.” |
---|
504 | |aIncludes bibliographical references. |
---|
520 | |a“Health Canada’s Pest Management Regulatory Agency (PMRA), under the authority of the Pest Control Products Act and Regulations, is granting full registration for the sale and use of Azamethiphos Technical and Salmosan Vet containing the technical grade active ingredient azamethiphos to control sea lice on farmed Atlantic salmon. This decision is consistent with the Proposed Registration Decision PRD2016-25, Azamethiphos, which contains a detailed evaluation of the information submitted in support of this registration. The evaluation found that, under the approved conditions of use, the product has value and does not present an unacceptable risk to human health or the environment. See Appendix I for a summary of comments received during the consultation process as well as the PMRA’s response to these comments"--p. 1. |
---|
530 | |aIssued also in print format. |
---|
692 | 07|2gccst|aInsecticides |
---|
692 | 07|2gccst|aCertification |
---|
692 | 07|2gccst|aToxicology |
---|
710 | 1 |aCanada. |bHealth Canada. |
---|
710 | 1 |aCanada. |bPest Management Regulatory Agency. |
---|
775 | 08|tAzaméthiphos |w(CaOODSP)9.842535 |
---|
830 | #0|aRegistration decision,|x1925-0940 ; |vRD2017-13|w(CaOODSP)9.505184 |
---|
856 | 40|qPDF|s537 KB|uhttps://publications.gc.ca/collections/collection_2017/sc-hc/H113-25/H113-25-2017-13-eng.pdf |
---|